Innoviva, Inc. (INVA) stock
INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3040% below fair value
$19.03+0.06 (+0.32%)
Close on Nov 13, 2026Market cap $1.37BP/E 9.7Yield –
Innoviva gross margin
Gross margin is gross profit as a percentage of revenue.
Innoviva's gross margin for the twelve months ending Sep 30, 2026 was 74.5%. For fiscal 2025 it was 74.8%, against 82.6% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 74.8% | −7.8 |
| FY2024 | Dec 31, 2024 | 82.6% | +3.3 |
| FY2023 | Dec 31, 2023 | 79.2% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 79.5% | +9.4 |
| Q2 FY2026 | Jun 30, 2026 | 75.8% | −7.1 |
| Q1 FY2026 | Mar 31, 2026 | 77.4% | −5.3 |
| Q4 FY2025 | Dec 31, 2025 | 66.0% | −19.1 |
| Q3 FY2025 | Sep 30, 2025 | 70.1% | −11.5 |
| Q2 FY2025 | Jun 30, 2025 | 82.9% | −2.2 |
| Q1 FY2025 | Mar 31, 2025 | 82.7% | +5.2 |
| Q4 FY2024 | Dec 31, 2024 | 85.1% | – |
| Q3 FY2024 | Sep 30, 2024 | 81.6% | – |
| Q2 FY2024 | Jun 30, 2024 | 85.1% | – |
| Q1 FY2024 | Mar 31, 2024 | 77.5% | – |
See a number that looks wrong?